- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
AARDEX Group Announces Partnerships On DiMe's Digital Medicine Society's V3+ Framework Project
This project has the ability to extend digital clinical measures to larger audiences.
Adherence specialists AARDEX Group announced its partnership with other industry leaders on DiMe Digital Medicine Society’s new Extending the Verification, Analytical Validation, and Clinical Validation (V3+) Framework project.
Organizations are taking digital clinical measures and products to scale, meaning digital health technologies (DHTs) must meet the needs of larger audiences. DiMe’s existing V3 Framework is the go-to guide for evaluating whether sensor-based DHTs are fit for purpose from a technical, scientific, and clinical performance of the product perspective.
The goal of the new V3+ project is to build on this success by adding evidence-based components that ensure DHTs meet the needs of all users through the application of best practices in usability, human factors, and human-centered design.
Continue reading this story here.
